Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-viral standards

This article was originally published in The Tan Sheet

Executive Summary

ASTM International test standards for assessing virucidal activity of handwash and handrub agents should be included in the OTC topical antimicrobial products final monograph, Microbiotest, Inc. asserts in recent comments to FDA. Lab also submits its protocol for study of hygienic handwash/handrub agent. "Recent upsurge" in viral infections necessitates anti-viral indications for antimicrobial products be included in rule alongside antibacterial claims, firm says. CTFA and SDA also support adding anti-viral indications (1"The Tan Sheet" Jan. 27, 2003, p. 7)...

You may also be interested in...



Anti-Viral Indications For Antimicrobial Products Urged By CTFA/SDA

The Cosmetic, Toiletry & Fragrance Association and Soap & Detergent Association are proposing a two-step approach to allowing both anti-viral and antibacterial claims on personnel hand products, food handler products and consumer handwash products

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel